OCUL Latest Headlines

OCUL’s OTX-TKI Extension Study: Long-Term Safety Data Could Shape Wet AMD Market

at www.tipranks.com (Wed, 1-Jul 12:31 PM)

William Blair updates conviction list: Oracle in, Meta out and more

at seekingalpha.com (Wed, 1-Jul 7:26 AM)

Ocular Therapeutix Awards New SVP With Inducement Grants—A Strategic Move to Boost Leadership and Pipeline Progress

Market Chameleon (Tue, 23-Jun 9:01 AM)

FDA Alignment Sets Up AXPAXLI for Potential First-in-Class Label: Ocular Therapeutix Eyes NDA Submission in Late 2026

Market Chameleon (Wed, 17-Jun 8:57 AM)

Ocular Therapeutix’s AXPAXLI Delivers Landmark Efficacy in Wet AMD—Regulatory and Commercial Milestones Take Center Stage

Market Chameleon (Tue, 5-May 8:32 AM)

Ocular Therapeutix Targets New Milestones With Packed May Conference Schedule and Clinical Updates

Market Chameleon (Mon, 27-Apr 9:39 AM)

Ocular Therapeutix’s SOL-1 Data Showcases Unmatched Durability for AXPAXLI in Wet AMD—23 to 22-Week Advantage Over Standard Treatment

Market Chameleon (Mon, 13-Apr 9:11 AM)